Mochida And Ayumi Launch Unique Humira Biosimilar Formulation In Japan
Launch And NHI Listing Follows Approval In March This Year
Executive Summary
A new formulation of biosimilar Humira is now available in Japan, alongside three other presentations that join biosimilar products launched by partners Viatris and Fujifilm Kyowa Kirin Biologics at the start of this year.
You may also be interested in...
AbbVie Sees Solid Japan Outlook Despite 2020 Dip
AbbVie expects double-digit sales growth in Japan over the mid-term despite a decline last year, driven in large part by multi-indication plans for new products.
Japan Approves First Humira Biosimilar
Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.
American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch
With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.